Giredestrant Promising New Treatment For Early-Stage HR-Positive Breast Cancer
Update: 2025-12-11
Description
After surgery, many people with stage I to stage III hormone receptor-positive breast cancer take tamoxifen or an aromatase inhibitor for five to 10 years. This has been the standard of care for the last 25 years.
At the 2025 San Antonio Breast Cancer Symposium, UCLA scientist Dr. Aditya Bardia presented results on giredestrant, a new oral selective estrogen degrader/downregulator (SERD) that offered better disease-free survival — how long people live without the cancer returning – than tamoxifen or an aromatase inhibitor.
Listen to the episode to hear Dr. Bardia explain:
- how giredestrant is different from the two other available SERDs
- if giredestrant could be combined with a CDK4/6 inhibitor
- giredestrant side effects
- what the results mean for people diagnosed with early-stage hormone receptor-positive breast cancer
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
